Bone Marrow-Derived Mononuclear Cells in the Treatment of Neurological Diseases: Knowns and Unknowns

iMSC: One leap closer to clinical applications

“…The findings not only validate the therapeutic potential of iMSCs but also offer unparalleled insights and support previously studies. 5 Notably, the authors demonstrate that both iMSCs and BMMSCs exhibit the capacity to attenuate infarct volumes after reperfusion, significant improvements in motor and cognitive functions for up to 56 days post-administration. A standout revelation was the suppression of microglial activation, proinflammatory cytokines, oxidative stress, and neuronal apoptosis, especially in the cerebral cortex’s ischemic border zone, by both iMSCs and BMMSCs.…”